Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

被引:2
作者
Peng, Xintong [1 ]
Zheng, Jingfan [1 ]
Liu, Tianzi [1 ]
Zhou, Ziwen [1 ]
Song, Chen [1 ]
Geng, Yan [1 ]
Wang, Zichuan [1 ]
Huang, Yan [2 ]
机构
[1] Weifang Med Univ, Sch Clin Med, Affiliated Hosp, Weifang, Peoples R China
[2] Weifang Med Univ, Dept Oncol, Affiliated Hosp, Weifang, Peoples R China
关键词
Tumor microenvironment; T-cells; immune system; cancer; macrophages; natural killer cells; immunotherapy; CANCER-ASSOCIATED FIBROBLASTS; CELL EFFECTOR FUNCTION; T-CELLS; MITOCHONDRIAL-DNA; IMMUNE-RESPONSE; STEM-CELLS; MACROPHAGES; METABOLISM; IMMUNOTHERAPY; MODULATION;
D O I
10.2174/1568009623666230712095021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective This review describes the comprehensive portrait of tumor microenvironment (TME). Additionally, we provided a panoramic perspective on the transformation and functions of the diverse constituents in TME, and the underlying mechanisms of drug resistance, beginning with the immune cells and metabolic dynamics within TME. Lastly, we summarized the most auspicious potential therapeutic strategies.Results TME is a unique realm crafted by malignant cells to withstand the onslaught of endogenous and exogenous therapies. Recent research has revealed many small-molecule immunotherapies exhibiting auspicious outcomes in preclinical investigations. Furthermore, some pro-immune mechanisms have emerged as a potential avenue. With the advent of nanosystems and precision targeting, targeted therapy has now transcended the "comfort zone" erected by cancer cells within TME.Conclusion The ceaseless metamorphosis of TME fosters the intransigent resilience and proliferation of tumors. However, existing therapies have yet to surmount the formidable obstacles posed by TME. Therefore, scientists should investigate potential avenues for therapeutic intervention and design innovative pharmacological and clinical technologies.
引用
收藏
页码:288 / 307
页数:20
相关论文
共 204 条
  • [81] Current Developments in the Preclinical and Clinical use of Natural Killer T cells
    Kratzmeier, Christina
    Singh, Sasha
    Asiedu, Emmanuel B.
    Webb, Tonya J.
    [J]. BIODRUGS, 2023, 37 (01) : 57 - 71
  • [82] Cancer immune therapy using engineered 'tail-flipping' nanoliposomes targeting alternatively activated macrophages
    Kuninty, Praneeth R.
    Binnemars-Postma, Karin
    Jarray, Ahmed
    Pednekar, Kunal P.
    Heinrich, Marcel A.
    Pijffers, Helen J.
    ten Hoopen, Hetty
    Storm, Gert
    van Hoogevest, Peter
    den Otter, Wouter K.
    Prakash, Jai
    [J]. NATURE COMMUNICATIONS, 2022, 13 (01)
  • [83] Mitophagy Plays an Essential Role in Reducing Mitochondrial Production of Reactive Oxygen Species and Mutation of Mitochondrial DNA by Maintaining Mitochondrial Quantity and Quality in Yeast
    Kurihara, Yusuke
    Kanki, Tomotake
    Aoki, Yoshimasa
    Hirota, Yuko
    Saigusa, Tetsu
    Uchiumi, Takeshi
    Kang, Dongchon
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (05) : 3265 - 3272
  • [84] Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion
    Lauder, Sarah N.
    Smart, Kathryn
    Bart, Valentina M. T.
    Pires, Ana
    Scott, Jake
    Milutinovic, Stefan
    Godkin, Andrew
    Vanhaesebroeck, Bart
    Gallimore, Awen
    [J]. BRITISH JOURNAL OF CANCER, 2022, 127 (09) : 1595 - 1602
  • [85] Cancer-associated fibroblasts in the single-cell era
    Lavie, Dor
    Ben-Shmuel, Aviad
    Erez, Neta
    Scherz-Shouval, Ruth
    [J]. NATURE CANCER, 2022, 3 (07) : 793 - 807
  • [86] Role of Mitochondrial Stress Response in Cancer Progression
    Lee, Yu Geon
    Park, Do Hong
    Chae, Young Chan
    [J]. CELLS, 2022, 11 (05)
  • [87] Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
    Leone, Robert D.
    Zhao, Liang
    Englert, Judson M.
    Sun, Im-Meng
    Oh, Min-Hee
    Sun, Im-Hong
    Arwood, Matthew L.
    Bettencourt, Ian A.
    Patel, Chirag H.
    Wen, Jiayu
    Tam, Ada
    Blosser, Richard L.
    Prchalova, Eva
    Alt, Jesse
    Rais, Rana
    Slusher, Barbara S.
    Powell, Jonathan D.
    [J]. SCIENCE, 2019, 366 (6468) : 1013 - +
  • [88] Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity
    Li, Anqi
    Chang, Yuzhou
    Song, No-Joon
    Wu, Xingjun
    Chung, Dongjun
    Riesenberg, Brian P.
    Velegraki, Maria
    Giuliani, Giuseppe D.
    Das, Komal
    Okimoto, Tamio
    Kwon, Hyunwoo
    Chakravarthy, Karthik B.
    Bolyard, Chelsea
    Wang, Yi
    He, Kai
    Gatti-Mays, Margaret
    Das, Jayajit
    Yang, Yiping
    Gewirth, Daniel T.
    Ma, Qin
    Carbone, David
    Li, Zihai
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (09)
  • [89] Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
    Li, Haohao
    Zhao, Alison
    Li, Menghua
    Shi, Lizhi
    Han, Qiuju
    Hou, Zhaohua
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [90] Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity
    Li, Yan-Ruide
    Brown, James
    Yu, Yanqi
    Lee, Derek
    Zhou, Kuangyi
    Dunn, Zachary Spencer
    Hon, Ryan
    Wilson, Matthew
    Kramer, Adam
    Zhu, Yichen
    Fang, Ying
    Yang, Lili
    [J]. CANCERS, 2022, 14 (11)